Vincent Rajkumar, Professor of Medicine at the Mayo Clinic in Rochester and Editor‑in‑Chief at Blood Cancer Journal, shared a post on X:
“Unprecedented. ASH25
Tec-Dara in relapsed myeloma.
Meanwhile here are some details on the trial, including slides on the design and safety profile.
Here is the full story and how this trial dramatically affects practice.”
More posts featuring Vincent Rajkumar on OncoDaily.
